Randomized, placebo-controlled, double-blind human pharmacology
CJC-1295
GH and IGF-1 increased for prolonged periods; this establishes pharmacodynamics, not broad performance/anti-aging benefits.
HUMAN EVIDENCE
What has actually reached humans?
Human participation alone does not establish efficacy. This page separates randomized efficacy work, pharmacology, physiology, observational evidence and limited clinical reports.
Human PK/PD + randomized phase 2
Ipamorelin
GH pharmacology demonstrated; postoperative-ileus phase-2 key efficacy endpoint was not statistically significant.
Human endocrine and pediatric growth studies
Sermorelin
Older literature demonstrates GH responses and growth-related outcomes in specific endocrine/pediatric settings.
Small randomized topical human study
GHK-Cu
Objective wrinkle/erythema outcomes did not significantly differ after CO₂ resurfacing; patient satisfaction differed.
Human physiologic / observational evidence
MOTS-c
Exercise changes endogenous MOTS-c in human muscle/circulation; exogenous intervention benefit remains primarily preclinical.
Human Tβ4 translational/clinical literature*
TB-500 / Tβ4
Human evidence concerns thymosin β4; commercial TB-500 identity must not be assumed.
Small comparative human studies
Selank
Published anxiety-related studies exist, but the base is small and regionally concentrated.
Human clinical reports
Semax
Stroke/rehabilitation publications exist, but they are not equivalent to a large modern multicenter evidence base.
Limited human reports; no published randomized efficacy result located
BPC-157
Most of the established literature remains preclinical. A historical Phase I registry record exists without a published result in the index.
No direct human therapeutic evidence located in launch review
KPV
Current index evidence is cellular/animal/review literature.
Important: “Human evidence” is deliberately broad here. Follow the compound page before drawing conclusions about design quality, sample size, endpoints, replication, formulation, or clinical relevance.